These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 1908431)

  • 1. Effect of pravastatin on newly-secreted very low density lipoprotein composition in rats.
    Yoshino G; Matsushita M; Iwai M; Morita M; Matsuba K; Hirano T; Furukawa S; Kazumi T; Baba S
    Horm Metab Res; 1991 Apr; 23(4):193-5. PubMed ID: 1908431
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of pravastatin sodium, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on very-low-density lipoprotein composition and kinetics in hyperlipidemia associated with experimental nephrosis.
    Hirano T; Komuro F; Furukawa S; Nagano S; Takahashi T
    Metabolism; 1990 Jun; 39(6):605-9. PubMed ID: 2112675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CS-514 (pravastatin) on VLDL-triglyceride kinetics in rats.
    Yoshino G; Kazumi T; Kasama T; Iwai M; Iwatani I; Matsuba K; Matsushita M; Baba S
    Atherosclerosis; 1988 Oct; 73(2-3):191-5. PubMed ID: 3142492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of pravastatin on hepatic metabolism of cholesterol.
    Hellerstein M
    N Engl J Med; 1991 Jan; 324(2):128. PubMed ID: 1898532
    [No Abstract]   [Full Text] [Related]  

  • 5. Very-low density lipoprotein metabolism.
    Eisenberg S
    Prog Biochem Pharmacol; 1979; 15():139-65. PubMed ID: 224393
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia.
    Pan HY; DeVault AR; Swites BJ; Whigan D; Ivashkiv E; Willard DA; Brescia D
    Clin Pharmacol Ther; 1990 Aug; 48(2):201-7. PubMed ID: 2116260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of pravastatin on serum cholesterol levels in hypercholesterolemic diabetic rabbits.
    Arbeeny CM; Bergquist KE
    Biochim Biophys Acta; 1991 Apr; 1096(3):238-44. PubMed ID: 1902119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lovastatin, pravastatin, and serum lipoprotein(a).
    Jacob BG; Richter WO; Schwandt P
    Ann Intern Med; 1990 May; 112(9):713-4. PubMed ID: 2139768
    [No Abstract]   [Full Text] [Related]  

  • 9. Studies on serum lipoproteins of rats developing spontaneous hyperlipidemia.
    Gustafsson K; Kiessling H
    Artery; 1981; 9(6):456-76. PubMed ID: 7337554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CS-514 suppresses plasma triglyceride in hypertriglyceridemic subjects without modifying a lipoprotein structural model.
    Yoshino G; Kazumi T; Iwai M; Kasama T; Iwatani I; Matsuba K; Inui A; Uenoyama R; Yokono K; Otsuki M
    Horm Metab Res; 1987 Oct; 19(10):513-4. PubMed ID: 3123351
    [No Abstract]   [Full Text] [Related]  

  • 11. Plasma lipoproteins in streptozotocin-diabetic rats, after Triton WR-1339 treatment.
    Takahashi K; Murase T; Yamada N; Iwamoto Y; Akanuma Y; Takaku F
    Horm Metab Res; 1984 Dec; 16 Suppl 1():82-4. PubMed ID: 6532938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of pravastatin and cholestyramine on circulating levels of parathyroid hormone and vitamin D metabolites.
    Ismail F; Corder CN; Epstein S; Barbi G; Thomas S
    Clin Ther; 1990; 12(5):427-30. PubMed ID: 2125243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production of apolipoprotein E-rich LDL by the liver. The effect of dietary cholesterol and some lipid lowering agents.
    Teramoto T; Matsushima T; Horie Y; Watanabe T
    Ann N Y Acad Sci; 1990; 598():301-7. PubMed ID: 2123378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin-sepharose 4B affinity chromatography of plasma very low density lipoprotein from streptozotocin-induced diabetic rats.
    Nakai T; Oida K; Tamai T; Kutsumi Y; Kobayashi T; Hayashi T; Takeda R; Yamada S
    Artery; 1982; 10(3):202-21. PubMed ID: 7103749
    [No Abstract]   [Full Text] [Related]  

  • 15. Hypolipidemic effect of intravenous pluronic L-81 in fasted rats treated with Triton WR-1339: possible inhibition of hepatic lipoprotein secretion.
    Nutting DF; Tso P
    Horm Metab Res; 1989 Mar; 21(3):113-5. PubMed ID: 2744715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of cholesterol-lowering on plasma membrane lipids and function.
    Lijnen P; Echevaría-Vázquez D; Petrov V
    Methods Find Exp Clin Pharmacol; 1996 Mar; 18(2):123-36. PubMed ID: 8740244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of rat brain prostaglandin D synthase by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Islam F; Watanabe Y; Hayaishi O
    Biochem Int; 1990 Nov; 22(4):601-5. PubMed ID: 2127671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes.
    Ouguerram K; Magot T; Zaïr Y; Marchini JS; Charbonnel B; Laouenan H; Krempf M
    J Pharmacol Exp Ther; 2003 Jul; 306(1):332-7. PubMed ID: 12684543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effect of rutin on lipids, lipoproteins, lipid metabolizing enzymes and glycoproteins in streptozotocin-induced diabetic rats.
    Stanely Mainzen Prince P; Kannan NK
    J Pharm Pharmacol; 2006 Oct; 58(10):1373-83. PubMed ID: 17034661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of established atherosclerosis and xanthomas in mature WHHL rabbits by keeping their serum cholesterol levels extremely low. Effect of pravastatin sodium in combination with cholestyramine.
    Shiomi M; Ito T; Watanabe Y; Tsujita Y; Kuroda M; Arai M; Fukami M; Fukushige J; Tamura A
    Atherosclerosis; 1990 Jul; 83(1):69-80. PubMed ID: 2117930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.